Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | GCK | P35557 | 3/20 | 0.71 |
| ▸ | GRM5 | P41594 | 1/20 | 0.70 |
| ▸ | SCD | O00767 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475830 | 0.87 | RAB9A (0.76) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL20662871 | 0.86 | MAPT (1.00) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL18550671 | 0.86 | NPC1 (1.00) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL8560618 | 0.85 | GCK (0.79) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL15283117 | 0.83 | RAB9A (0.74) | NPC1RAB9AMAPTGCKSCD | |
| SCHEMBL8124814 | 0.83 | RAB9A (0.70) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL21221226 | 0.83 | GCK (0.72) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL7350718 | 0.83 | GCK (0.72) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL16607176 | 0.82 | MAPT (0.80) | NPC1RAB9AMAPTGCKGRM5 | |
| SCHEMBL3509220 | 0.82 | NPC1 (0.75) | NPC1RAB9AMAPTGCKGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580404-A2 | SULFONAMIDE APYRASE INHIBITORS | Texas Crop Science, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024050041-A2 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE (US) | 2024-03-07 | — | — | WO | claimed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | claimed |
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | claimed |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210330646-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | SPINOGENIX, INC. | 2021-10-28 | — | — | US | disclosed |
| US-9650369-B2 | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease | XAVIER UNIVERSITY OF LOUISIANA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650369-B2 | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease | XAVIER UNIVERSITY OF LOUISIANA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | disclosed |
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | XAVIER UNIVERSITY OF LOUISIANA | 2015-10-01 | — | — | US | disclosed |
| EP-2459554-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | disclosed |
| EP-2445908-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011013141-A2 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010150280-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-29 | — | — | WO | disclosed |
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274714-A1 | ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE | MKI67, MIF, NUDC | NPC1 189/4885RAB9A 1305/4885MAPT 3002/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | NPC1 3105/4885RAB9A 2752/4885MAPT 3292/4885 |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | APEH, ARSA, DNPEP | NPC1 3337/4885RAB9A 1777/4885MAPT 4236/4885 |
| US-20210330646-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | FSCN1, SMN1; SMN2, DCX | NPC1 4121/4885RAB9A 931/4885MAPT 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.